Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Current Leases: 2019-2025

Historic Current Leases for Editas Medicine (EDIT) over the last 7 years, with Sep 2025 value amounting to $6.1 million.

  • Editas Medicine's Current Leases fell 62.86% to $6.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.1 million, marking a year-over-year decrease of 62.86%. This contributed to the annual value of $14.7 million for FY2024, which is 20.45% up from last year.
  • As of Q3 2025, Editas Medicine's Current Leases stood at $6.1 million, which was down 0.94% from $6.1 million recorded in Q2 2025.
  • In the past 5 years, Editas Medicine's Current Leases registered a high of $18.2 million during Q2 2024, and its lowest value of $6.1 million during Q3 2025.
  • Over the past 3 years, Editas Medicine's median Current Leases value was $12.2 million (recorded in 2023), while the average stood at $11.6 million.
  • As far as peak fluctuations go, Editas Medicine's Current Leases soared by 76.03% in 2024, and later slumped by 66.20% in 2025.
  • Quarterly analysis of 5 years shows Editas Medicine's Current Leases stood at $10.3 million in 2021, then climbed by 7.50% to $11.1 million in 2022, then rose by 9.76% to $12.2 million in 2023, then grew by 20.45% to $14.7 million in 2024, then crashed by 62.86% to $6.1 million in 2025.
  • Its last three reported values are $6.1 million in Q3 2025, $6.1 million for Q2 2025, and $13.2 million during Q1 2025.